BACKGROUND: The amygdala is a limbic structure involved in the stress response and the regulation of emotional behaviors, both of which are disrupted in patients with neuropsychiatric illnesses. Because glucocorticoids are mediators of the stress response, we hypothesized that glucocorticoid receptor (GR) messenger ribonucleic acid (mRNA) levels might be altered in the amygdala. We also hypothesized that estrogen receptor alpha (ERalpha) mRNA expression might be altered in the amygdala, on the basis of observed gender differences in mental illness. METHODS: Using quantitative film autoradiography after in situ hybridization with human GR and ERalpha probes, we measured mRNA levels on adjacent amygdala sections in four groups (n = 15 each of subjects with schizophrenia, major depressive disorder, and bipolar disorder, and unaffected control subjects) provided by the Stanley Consortium. RESULTS: We detected main effects of diagnosis and exposure to antidepressant medication on the levels of both mRNAs but no main effect of gender. Compared with control subjects, GR mRNA expression was reduced in the basolateral/lateral nuclei in schizophrenia and bipolar disorder. Estrogen receptor alpha mRNA levels were reduced in the basomedial nucleus in major depressive disorder and bipolar disorder. CONCLUSIONS: Our results support and extend previous findings describing a pattern of steroid hormone mRNA alterations that differs depending on which brain region is being examined in a given mental illness.
BACKGROUND: The amygdala is a limbic structure involved in the stress response and the regulation of emotional behaviors, both of which are disrupted in patients with neuropsychiatric illnesses. Because glucocorticoids are mediators of the stress response, we hypothesized that glucocorticoid receptor (GR) messenger ribonucleic acid (mRNA) levels might be altered in the amygdala. We also hypothesized that estrogen receptor alpha (ERalpha) mRNA expression might be altered in the amygdala, on the basis of observed gender differences in mental illness. METHODS: Using quantitative film autoradiography after in situ hybridization with humanGR and ERalpha probes, we measured mRNA levels on adjacent amygdala sections in four groups (n = 15 each of subjects with schizophrenia, major depressive disorder, and bipolar disorder, and unaffected control subjects) provided by the Stanley Consortium. RESULTS: We detected main effects of diagnosis and exposure to antidepressant medication on the levels of both mRNAs but no main effect of gender. Compared with control subjects, GR mRNA expression was reduced in the basolateral/lateral nuclei in schizophrenia and bipolar disorder. Estrogen receptor alpha mRNA levels were reduced in the basomedial nucleus in major depressive disorder and bipolar disorder. CONCLUSIONS: Our results support and extend previous findings describing a pattern of steroid hormone mRNA alterations that differs depending on which brain region is being examined in a given mental illness.
Authors: David N Herndon; Charles D Voigt; Karel D Capek; Paul Wurzer; Ashley Guillory; Andrea Kline; Clark R Andersen; Gordon L Klein; Ronald G Tompkins; Oscar E Suman; Celeste C Finnerty; Walter J Meyer; Linda E Sousse Journal: Ann Surg Date: 2016-09 Impact factor: 12.969
Authors: Antonia N Kaczkurkin; Tyler M Moore; Kosha Ruparel; Rastko Ciric; Monica E Calkins; Russell T Shinohara; Mark A Elliott; Ryan Hopson; David R Roalf; Simon N Vandekar; Efstathios D Gennatas; Daniel H Wolf; J Cobb Scott; Daniel S Pine; Ellen Leibenluft; John A Detre; Edna B Foa; Raquel E Gur; Ruben C Gur; Theodore D Satterthwaite Journal: Biol Psychiatry Date: 2016-05-09 Impact factor: 13.382
Authors: Ming-Fen Ho; Cristina Correia; James N Ingle; Rima Kaddurah-Daouk; Liewei Wang; Scott H Kaufmann; Richard M Weinshilboum Journal: Biochem Pharmacol Date: 2018-04-03 Impact factor: 5.858